{{Rsnum
|rsid=3130660
|Gene=FLOT1
|Chromosome=6
|position=30738584
|Orientation=plus
|GMAF=0.0427
|Assembly=GRCh38
|GenomeBuild=38.1
|dbSNPBuild=141
|geno1=(A;A)
|geno2=(A;T)
|geno3=(T;T)
|Gene_s=FLOT1
}}{{ population diversity
| geno1=(A;A)
| geno2=(A;T)
| geno3=(T;T)
| CEU | 0.0 | 32.3 | 67.7
| HCB | 0.0 | 0.0 | 100.0
| JPT | 0.0 | 0.0 | 100.0
| YRI | 0.0 | 6.3 | 93.7
| ASW | 0.0 | 0.0 | 0.0
| CHB | 0.0 | 0.0 | 100.0
| CHD | 0.0 | 0.0 | 0.0
| GIH | 0.0 | 0.0 | 0.0
| LWK | 0.0 | 0.0 | 0.0
| MEX | 0.0 | 0.0 | 0.0
| MKK | 0.0 | 0.0 | 0.0
| TSI | 0.0 | 0.0 | 0.0
| HapMapRevision=28
}}{{PharmGKB
|RSID=rs3130660
|Name_s=
|Gene_s=FLOT1
|Feature=
|Evidence=PubMed ID:16998491
|Annotation=Risk or phenotype-associated allele: allele 1. Phenotype: Combined alleles of rs3130660 (1) and rs1063635 (1) are tagging SNPs for HLA-B*5801. Study size: 182. Study population/ethnicity: Caucasians Utah residents (29 extended families with an average family size of 6.2, containing 45 unrelated parent-offspring trios) of European ancestry, from the Centre d'Etude du Polymorphisme Humain (CEPH) collection (CEU). Significance metric(s): Type of association: GN
|Drugs=
|Drug Classes=
|Diseases=
|Curation Level=Curated
|PharmGKB Accession ID=PA165291977
}}

{{GET Evidence
|impact=pharmacogenetic
|qualified_impact=Insufficiently evaluated pharmacogenetic
|inheritance=unknown
|quality_scores=Array
|dbsnp_id=rs3130660
|overall_frequency_n=8
|overall_frequency_d=128
|overall_frequency=0.0625
|n_genomes=7
|n_genomes_annotated=0
|n_haplomes=7
|n_articles=1
|n_articles_annotated=0
|in_pharmgkb=Y
|autoscore=1
|webscore=N
}}

{{on chip | 23andMe v1}}
{{on chip | 23andMe v2}}
{{on chip | 23andMe v3}}
{{on chip | 23andMe v4}}
{{on chip | HumanOmni1Quad}}